Targeted treatment for lymphoma spread to the brain
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of chemotherapy and a targeted drug (zanubrutinib) for people with a type of lymphoma (DLBCL) that has spread to the brain or spinal fluid. The goal is to see if this treatment can better control the disease and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with DLBCL that has spread to the brain or spinal fluid, and you have not yet received treatment for it.
- You are generally able to care for yourself (ECOG score 0-3).
- Your blood counts, liver, kidney, and heart function are within acceptable levels for the study.
- You have not had chemotherapy, radiation, or antibody therapy in the last 3 weeks, or targeted therapy in the last 10 days.
- If you are of childbearing potential, you agree to use effective birth control during and for at least 90 days after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests whether adding either methotrexate or thiotepa to the standard R-CHOP regimen plus orelabrutinib can better treat diffuse large B-cell lymphoma (DLBCL) that has spread to the central nervous system (brain or spinal cord). The goal is to see if these combinations improve outcomes for patients with this type of lymphoma.
This trial tests a new targeted drug (pirtobrutinib) combined with standard chemotherapy and immunotherapy for people with a fast-growing lymphoma that has spread to the brain or spinal cord. The goal is to see if this combination can more effectively treat the lymphoma in these hard-to-reach areas.
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.